Cepheid to Sponsor BASHH 2013 Spring Meeting
News May 07, 2013
Event is where the latest healthcare trends and scientific breakthroughs in this important field will be discussed.
A platinum sponsor of the event – held from the 15th to the 17th of May in Bristol – Cepheid will be showcasing the latest addition to the GeneXpert® test menu, Xpert® CT/NG, on booth 19 at the accompanying exhibition.
The meeting’s diverse programme includes a Cepheid-sponsored lecture on Assessing the costs and benefits of point of care tests for STIs from invited speaker Dr Elisabeth Adams, Director and Founder of Aquarius Population Health and an Honorary Researcher at the University of Bristol. Visitors to the Cepheid exhibition stand will discover the advantages of the Xpert CT/NG qualitative in vitro molecular diagnostic test for the rapid detection and differentiation of Chlamydia trachomatis (CT) and Neisseria gonorrhoeae (NG). This easy-to-use, FDA-approved and CE-marked on-demand molecular test uses two independent NG DNA targets for high specificity and a CT target exclusively selected for superior inclusivity. A Sample Adequacy Control (SAC) is also included, to prevent false negative results where no human cells are present. Accurate results are delivered in just 90 minutes, contributing to effective patient and disease management by giving clinicians the opportunity to provide same-day consultation and treatment.
When the Human Genome Project was completed, in 2003, it opened the door to a radical new idea of health - that of personalized medicine, in which disease risk and appropriate treatment would be gleaned from one's genetic makeup. In a new article, researchers discuss how gene interaction networks hold the clues to disease susceptibility and treatment response.READ MORE
Researchers have developed an artificial intelligence platform to detect a range of neurodegenerative diseases in human brain tissue samples, including Alzheimer’s disease and chronic traumatic encephalopathy. Their discovery will help scientists develop targeted biomarkers and therapeutics, resulting in a more accurate diagnosis of complex brain diseases.READ MORE